Under construction – not a live service

Skip to content

Frontlight Research

Institution

Union Hospital

Fuzhou, ChinahealthcareWebsite

Also known as: Fujian Medical University Union Hospital

187running trials
55closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

The site has not confirmed any trial yet.

Running trials

Not yet recruiting
Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 Hours
NCT07912970· Phase 3· Source
Not yet recruiting
Tenecteplase in Acute Ischemic Stroke Under Different Transfer Models
NCT07897955· Source
Not yet recruiting
Real-World Study: Panitumumab N01 vs Cetuximab Plus FOLFOX in First-Line RAS Wild-Type mCRC
NCT07917429· Source
Not yet recruiting
Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer
NCT07314203· Phase 3· Source
Not yet recruiting
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
NCT07720193· Phase 3· Source
Recruiting
Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure
NCT07575672· Phase 3· Source
Recruiting
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
NCT07717411· Phase 3· Source
Not yet recruiting
A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer
NCT07788001· Phase 3· Source
Recruiting
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07795346· Phase 3· Source
Not yet recruiting
A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
NCT07767188· Phase 3· Source
Recruiting
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007· Phase 2· Source
Recruiting
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
NCT07518043· Phase 1· Source
Recruiting
Catheter-Oriented Unloading and Recovery With a Left Ventricular Assist Gear: Efficacy in Post Cardiotomy Cardiogenic Shock
NCT07560085· Source
Not yet recruiting
Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)
NCT07669363· Phase 2· Source
Recruiting
A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis
NCT07551427· Phase 2· Source
Active, not recruiting
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
NCT07684898· Phase 3· Source
Recruiting
Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
NCT07552402· Source
Not yet recruiting
Computer Vision-Based Recognition of Parathyroid Glands and Recurrent Laryngeal Nerves in Endoscopic Surgery
NCT07628543· Source
Not yet recruiting
The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy
NCT07406815· Phase 3· Source
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· Phase 2/3· Source
Recruiting
Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation
NCT07444372· Source
Recruiting
A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer
NCT07462143· Phase 2/3· Source
Recruiting
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
NCT07571161· Phase 3· Source
Recruiting
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
NCT07416604· Phase 3· Source
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995· Phase 3· Source
Recruiting
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703· Phase 3· Source
Active, not recruiting
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
NCT07663903· Phase 3· Source
Recruiting
RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
NCT07541521· Source
Recruiting
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT07409428· Phase 3· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· Phase 3· Source
Recruiting
Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
NCT07528066· Source
Not yet recruiting
Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window
NCT07476898· Phase 3· Source
Not yet recruiting
Rezvilutamide for High-Risk Prostate Cancer After Surgery
NCT07444983· Source
Active, not recruiting
Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca
NCT07493070· Source
Active, not recruiting
HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
NCT07462923· Phase 1· Source
Not yet recruiting
The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy
NCT07303231· Phase 3· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357· Phase 2/3· Source
Recruiting
Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients
NCT07266116· Phase 1/2· Source
Recruiting
Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
NCT07419932· Source
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· Phase 3· Source
Recruiting
Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2
NCT07263308· Phase 3· Source
Not yet recruiting
A Prospective, Single-center, Randomized Controlled Clinical Study Evaluating the Efficacy and Safety of Hyperbaric Oxygen Therapy as an Adjunctive Treatment for Chronic Heart Failure
NCT07311109· Source
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800· Phase 3· Source
Recruiting
A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
NCT07182682· Phase 3· Source
Not yet recruiting
A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS
NCT07169175· Phase 1/2· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310· Phase 3· Source
Recruiting
Evaluation of the Safety and Effectiveness of CHORDS® Cerebral Protection System During TAVR: DUET Trial
NCT07648693· Source
Recruiting
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
NCT07296705· Phase 2· Source
Recruiting
Haplo-Cord HSCT for AML/MDS
NCT07588360· Source
Recruiting
Balloon Guide Catheter to Optimize Outcomes in Stroke Thrombectomy of the Internal Carotid Artery
NCT07192029· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Gastric and esophageal cancer22 recruiting
Lung cancer16 recruiting
Childhood cancers13 recruiting
Stroke11 recruiting
Thyroid cancer9 recruiting
Colorectal cancer7 recruiting
Alzheimer disease6 recruiting
Acute myeloid leukemia5 recruiting
Metastatic breast cancer5 recruiting
Acute lymphoblastic leukaemia4 recruiting
Bladder cancer4 recruiting
Chronic lymphocytic leukaemia3 recruiting
Prostate cancer3 recruiting
ALS (motor neurone disease)2 recruiting
Diffuse large B-cell lymphoma2 recruiting
Heart failure2 recruiting
Kidney cancer2 recruiting
Liver and biliary tract cancer2 recruiting
Lupus (SLE)2 recruiting
Mantle cell lymphoma2 recruiting
Multiple myeloma2 recruiting
Myelodysplastic syndromes2 recruiting
Parkinson disease2 recruiting
Triple-negative breast cancer2 recruiting
Amyloidosis1 recruiting
Atrial fibrillation1 recruiting
Cervical cancer1 recruiting
CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
COPD1 recruiting
Coronary artery disease1 recruiting
Follicular lymphoma1 recruiting
Haemophilia1 recruiting
IgA nephropathy1 recruiting
Melanoma1 recruiting
Mesothelioma1 recruiting
Myeloproliferative neoplasms1 recruiting
Neuroendocrine tumours1 recruiting
Ovarian cancer1 recruiting
Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

Completed
A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects
NCT07357831· Phase 3· Source
Recruiting
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
NCT06842199· Phase 3· Source
Completed
Phase IIa Study for IPG11406 in Patients With Lupus Nephritis
NCT06717815· Phase 1/2· Source
Completed
Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
NCT06738485· Phase 3· Source
Completed
Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis
NCT06631170· Phase 3· Source
Completed
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT06601504· Phase 2· Source
Completed
Trajectory of Body Composition Identifies LAGC with Cachexia Following NACT
NCT06716593· Source
Completed
AI-Assisted Ultrasound Review Before Thyroid Surgery
NCT06498674· Source
Completed
HTA of NIVATS Based on RWE
NCT06574295· Source
Completed
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
NCT06241313· Phase 3· Source
Completed
Impact of TTC Following Neoadjuvant Chemotherapy on the Prognosis of LAGC
NCT06696963· Source
Completed
Endovascular Treatment for Mild Stroke With Acute Anterior Circulation Large Vessel Occlusion
NCT06179017· Source
Completed
The Safety and Efficiency of Stent-based Diverting Technique Versus Ileostomy in Rectal Cancer Patients
NCT06204497· Source
Completed
Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
NCT06142552· Phase 3· Source
Completed
Appraisal of the Modified Cancer Cachexia Index in Locally Advanced Gastric Cancer Patients Undergoing Neoadjuvant Chemotherapy
NCT06689462· Source
Completed
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
NCT06010303· Phase 2· Source
Completed
Predict 5-Year Survival in Elderly Gastric Cancer
NCT06208046· Source
Completed
Efficacy, Safety of Astragalus Membranaceus in Mild-to-Moderate Alzheimer's Disease
NCT06694597· Phase 2· Source
Completed
Study of Telitacicept in Generalized Myasthenia Gravis
NCT05737160· Phase 3· Source
Completed
A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
NCT05707351· Phase 3· Source
Completed
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
NCT05577702· Phase 2· Source
Completed
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT05687032· Phase 4· Source
Completed
A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)
NCT05810948· Phase 2· Source
Completed
A Novel Online Calculator to Predict Long-term Survival and Recurrence Risk of Patients With Gastric Adenocarcinoma
NCT06337266· Source
Completed
Systemic Oxidative Stress Score as a Predictor of Gastric Cancer Survival and Recurrence Risk
NCT06337279· Source
Completed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
NCT06846099· Phase 1· Source
Completed
Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.
NCT06376773· Source
Completed
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT05052801· Phase 3· Source
Terminated
Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer
NCT05149807· Phase 2/3· Source
Completed
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
NCT05228470· Phase 2· Source
Recruiting
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173· Phase 3· Source
Completed
A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)
NCT05083923· Phase 3· Source
Recruiting
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
NCT04973605· Phase 1/2· Source
Completed
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
NCT05054751· Phase 3· Source
Recruiting
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622· Phase 3· Source
Terminated
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
NCT04551053· Phase 3· Source
Terminated
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
NCT04551066· Phase 3· Source
Completed
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
NCT04805307· Phase 1· Source
Completed
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT04513925· Phase 3· Source
Completed
Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer
NCT04195828· Phase 2· Source
Completed
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
NCT04108208· Phase 4· Source
Completed
Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma
NCT04009265· Phase 3· Source
Completed
Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
NCT04005716· Phase 3· Source
Completed
TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
NCT03952091· Phase 3· Source
Terminated
A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
NCT03758417· Phase 2· Source
Completed
Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment
NCT04085276· Phase 3· Source
Completed
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
NCT03675737· Phase 3· Source
Completed
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT03734016· Phase 3· Source
Completed
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
NCT03588091· Phase 3· Source
Completed
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
NCT03371017· Phase 3· Source

Trial sites

Conditions

Diseases this institution publishes on or runs trials for.

Gastric and esophageal cancer79 works · 44 trials
Acute myeloid leukemia33 works · 7 trials
Diffuse large B-cell lymphoma12 works · 3 trials
Myasthenia gravis10 works · 6 trials
Follicular lymphoma6 works · 5 trials
Haemophilia6 works · 6 trials

Institution data: ROR 055gkcy74 (CC0-1.0)Updated 10 Nov 2026

Report an error